Introduction
Hypothalamic hamartoma is a rare but now well recognised pathology causing drug resistant epilepsy, including the pathognomonic gelastic and dacrystic seizures, with marked cognitive and behaviour problems in many. Some however present primarily with precocious puberty, and seizures are not an obvious feature (although they may become evident in retrospect). Medical management is targeted at seizure control and/or delaying or monitoring precocious puberty and growth. In the absence of more conventional seizure types, the biggest challenge remains in diagnosing the seizures, which may remain unrecognised for some time: once diagnosed however, they remain resistant to antiepileptic medications
Making an accurate diagnosis
Accurate diagnosis poses challenges. Patients may be referred in one of two ways -to endocrinologists for investigation of precocious puberty, or alternatively to neurologists for evaluation of epileptic seizures. The pathognomonic seizure type, gelastic seizures, characterized by spontaneous mirthless laughter, often in isolation, are often missed at onset and may remain undiagnosed for some time. Older children and adults do not generally report a feeling of mirth; many report an unpleasant sensation or epigastric discomfort, or indeed a pressure to laugh. In its mildest form, patients may simply report an urge to laugh that can be suppressed. In addition dacrystic, or 'crying' seizures may also be seen but again may go unrecognised. It may only be with the manifestation of more typical epileptic seizures, such as evolution to convulsive seizures, that a diagnosis in retrospect may be made.
Although seizures appear the most common presentation to neurology (61%) a significant proportion have (in some unrecognised) precocious puberty at presentation (66%) whilst 25% present with evidence of both 1 . Age at presentation is wide; however early onset gelastic seizures in the first year of life are often missed or misdiagnosed as reflux or 
Initiation of treatment
The evidence base for the optimal anticonvulsants to use in epilepsy associated with hypothalamic hamartoma, is limited. Most reports comment on medication failure and drug resistance with no particular useful therapy 8 . On assessment at diagnosis of gelastic seizures it is likely a usual protocol for focal seizures will be followed, such as carbamazepine or lamotrigine in the first instance. There is little evidence of response however. Anecdotal evidence suggests zonisamide may be of some benefit. However it also has to be considered that many series are reported from surgical centres and therefore likely to have a bias toward a drug resistant group. There is no question there appears to be a degree of variability in the clinical course, and not all inevitably demonstrate an evolution to marked behaviour and cognitive difficulty, remaining with gelastic seizures alone for many years 9 . In others where precocious puberty has been the prominent presentation, seizures may be entirely absent, diagnosed in retrospect, or where they do occur follow a relatively benign course responding to a variety of different medications 10 . However, individual risk benefit may need to be considered in each case, the aims of treatment being to minimise progression to convulsive seizures rather than reducing gelastic or dacrystic seizures per se, which do not alone appear detrimental to learning. We have no data as to whether medication makes any difference to the natural history of the condition, or on any longer term benefit. In the presence of convulsive seizures treatment is probably justifed, but in the presence of gelastic or dacrystic seizures alone, the data favouring medical therapy remain limited.
Why are seizures so drug resistant?
The results of EEG recordings from within the hamartoma, and indeed data from surgical series, demonstrate that the epileptic activity originates from within the hamartoma 11;12 .
One might speculate that routine anti epileptic medications would poorly penetrate into such a lesion, and hence the poor response of localised gelastic and dacrystic seizures.
However, studies of epileptogenesis of tissue from within such lesions suggest that the available antiepileptic agents have a mode of action irrelevant to these lesions. GABAA receptor mediated activation of L-type calcium channels induce neuronal excitation in excised tissue in vitro 13 , and blockade of these channels utilising nifedipine modulates the pathogenic high frequency oscillations in hypothalamic epileptogenic tissue; however this
has not yet translated to clinical practice 14 and the role of the newer agents remains untested.
In a significant proportion of children presenting with gelastic seizures, progression is seen over time with the development of other seizure types, increasing cognitive and behaviour difficulties with more evident and/or widespread changes on EEG suggestive of a more widespread encephalopathy. Management should be targeted at preventing such an evolution, with post surgical studies demonstrating a degree of resolution in some cases 15 .
The ketogenic diet, a high fat, low carbohydrate, low protein diet, has been used in refractory epilepsy in children for many years. It has been demonstrated to be of benefit in a randomised controlled trial of children with refractory epilepsy of many different types as compared to no change in treatment 16 . It has also been demonstrated to be of particular benefit in children with epilepsy resulting from malformations of cortical development 17 . One publication reports on the use of the ketogenic diet in children with epilepsy associated with hypothalamic hamartoma; 10/220 children were retrospectively determined to have been treated, with outcome data available in 6. These had been commenced on the diet at a mean age of 12 years, for a median duration of 9 months, although one child who particularly benefitted, continued for 14 years 18 . Four had a 50-90% reduction in multiple seizure types, including gelastic, focal and atonic seizures, and two failed to respond. Possible mechanisms of action were studied utilising microelectrode recordings of small neurons in HH slices; decreased spontaneous firing was seen on exposure to ketone bodies, suggesting a possible benefit in this population.
Beyond the seizures -optimising management
Seizures of course do not present the only aspect of medical management for these Further behavioural assessment with psychiatric input where required is likely to be of help to families and schools. In such circumstances where behaviour is of concern , there should be early referral for consideration of surgery.
Guidelines on management
A high degree of suspicion is required to ensure appropriate imaging and consequently reach a diagnosis of epilepsy associated with hypothalamic hamartoma. On diagnosis however, although antiepileptic medication should be initiated, referral to a specialist surgical centre should be facilitated so careful followup and appropriate medical/surgical decisions are made. Recognising the lack of response of gelastic/dacrystic seizures to antiepileptic medication, it is not unreasonable to consider holding off medication at this stage. However full endocrine review should be undertaken. Careful regular evaluation should be ensured, including EEG, and, dependent on the type of lesion and clinical manifestation consideration given to early resection or ablation. Antiepileptic medication should certainly be considered with presentation of other seizure types, although the risk benefit of any treatment needs to be considered in individual cases.
What is foreseen in the future?
What is clear on reviewing the literature to date is that many reported observational series have a particular bias according to the centre, especially surgical. In the absence of a comprehensive HH registry of all children, what is difficult to determine is the true prevalence and range of neuro-endocrine presentations, and the overall natural history of the condition with and without intervention, according to radiological features. Of importance is to define which children would benefit from early surgical intervention, and in whom it may be avoided dependent on the risk-benefit ratio. The exceptional rarity of the condition mandates a concerted multicentre and multi professional effort to develop medical protocols for investigation and assessment and a core data set for monitoring neuro developmental and endocrine outcomes in relation to therapy, with pathways in place for early evaluation of appropriate surgical intervention.
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